• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Circulating Endothelial Progenitor and Mesenchymal Stromal Cells as Biomarkers for Monitoring Disease Status and Responses to Exercise
Rev Cardiovasc Med. 2022 Dec 2;23(12):396. doi: 10.31083/j.rcm2312396.ABSTRACTNoncommunicable chronic diseases, such as obesity, cardiovascular disease (CVD), and type 2 diabetes (T2D), pose significant health challenges globally. Important advances have been made in the understanding of the pathophysiologal mechanisms and treatment of noncommunicable diseases in recent years. Lack of physical activity is a primary contributor to many noncommunicable diseases including metabolic syndrome, T2D, CVD, and obesity. Certain diabetes medications and non-pharmaceutical interventions, such as physical activity and exercise, are sh...
Source: Reviews in Cardiovascular Medicine - September 8, 2023 Category: Cardiology Authors: Jared M Gollie Sabyasachi Sen Source Type: research

Influence of clonal hematopoiesis on non-hematological diseases and aging processes
Inn Med (Heidelb). 2022 Oct 10. doi: 10.1007/s00108-022-01409-6. Online ahead of print.ABSTRACTThe occurrence of clonal hematopoiesis, caused by acquired somatic mutations of leukemia-associated genes in blood stem cells is very common in the population and increases with age. Besides an increased risk of developing myeloid neoplasms, an unexpected causal relationship between clonal hematopoiesis and cardiovascular diseases was recently discovered. Clonal hematopoiesis presents as a new independent and strong risk factor for cardiovascular diseases, such as atherosclerosis, coronary heart disease, heart failure, aortic val...
Source: Atherosclerosis - October 10, 2022 Category: Cardiology Authors: Michael A Rieger Source Type: research

Evidence of Clonal Hematopoiesis and Risk of Heart Failure
AbstractPurpose of ReviewClonal hematopoiesis of indeterminate potential (CHIP) is characterized by persistent clonal expansion of adult hematopoietic stem cells, which has been increasingly found to be associated with cardiovascular disease and adverse outcomes in heart failure. Here we outline emerging studies on the prevalence of CHIP, and its association with cardiovascular and heart disease.Recent FindingsPrevious genomic studies have found CHIP mutations to be associated with increased risks of arterial disease, stroke, and mortality. Murine studies exploringTET2,DNMT3A, andJAK2 mutations have shown changes in cellul...
Source: Current Heart Failure Reports - August 8, 2020 Category: Cardiology Source Type: research

Safety and Efficacy of Intracoronary Infusion of Allogeneic Human Cardiac Stem Cells in Patients with ST-segment Elevation Myocardial Infarction and Left Ventricular Dysfunction: A Multicenter Randomized, Double-Blind and Placebo-Controlled Clinical Trial.
Conclusions: Allogeneic cardiac stem cells can be safely administered in STEMI patients with LV dysfunction early after revascularization. Low immunogenicity and absence of immune-mediated events will facilitate adequately powered studies to demonstrate their clinical efficacy in this setting.Clinical Trial Registration: NCT 02439398. PMID: 29921651 [PubMed - as supplied by publisher]
Source: Circulation Research - June 19, 2018 Category: Cardiology Authors: Fernández-Avilés F, Sanz-Ruiz R, Bogaert J, Casado Plasencia A, Gilaberte I, Belmans A, Fernández-Santos ME, Charron D, Mulet M, Yotti R, Palacios I, Luque M, Sádaba R, San Roman JA, Larman M, Sánchez PL, Sanchis J, Jimenez-Navarro MF, Claus P, Al-Da Tags: Circ Res Source Type: research

Stem Cell Therapies for Cardiovascular Diseases: What Does the Future Hold?
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality around the globe. In Australia, one in six people are affected by CVD and a total of 4.2 million people are suffering from heart disease, stroke or vascular disease. Coronary artery disease affects around 1.2 million Australians, many of whom develop chronic heart failure as a result of ischaemic cardiomyopathy. The management of CVD has evolved tremendously in the past three decades, but the majority of treatments are not curative.
Source: Heart, Lung and Circulation - January 24, 2017 Category: Cardiology Authors: Hai-Ying Chen, Padraig Michael Strappe, Le-xin Wang Tags: Editorial Source Type: research